Guggenheim Maintains Buy on Vaxcyte, Raises Price Target to $125

Benzinga Newsdesk www.benzinga.com Positive 74.1%

Neg 0% Neu 0% Pos 74.1%

Guggenheim analyst Seamus Fernandez maintains Vaxcyte (NASDAQ:PCVX) with a Buy and raises the price target from $116 to $125.